Navigation Links
Clinical trial will test new HIV/AIDS vaccine
Date:4/3/2008

BOSTON A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Womens Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine, explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study.

The vaccine consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.

The rAd26 vaccine vector was selected for its particularly low seroprevalence in human populations and for its potent immunogenicity and protective efficacy in preclinical studies, explains Dan H. Barouch, MD, PhD, Associate Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School and Principal Investigator of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program that developed the vaccine. This program is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Manufactured by the Dutch biotechnology company Crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccine candidates. The novel strategy used in developing this vaccine enables researchers to circumvent preexisting immunity to the adenovirus serotype 5, the virus responsible for the common cold, which has recently shown limitations as an HIV-1 vaccine vector.

The rAd26 vector does not regularly occur in the human population and human antibodies to this vector are rare, explains Jaap Goudsmit, Chief Scientific Officer at Crucell. The rAd26 vector therefore is efficacious in eliciting good T and B cell responses.

AIDS remains one of the worlds most devastating health problems, with an estimated 33.2 million people living with HIV/AIDS and 2.5 million new infections reported in 2007 alone.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology: